McGowan Institute for Regenerative Medicine Deputy Director Stephen Badylak, DVM, PhD, MD, a nationally recognized pioneer in stem cell and tissue regeneration, will receive BioMed SA’s 2019 Award for Innovation in Healthcare and Bioscience in San Antonio, Texas, September 19, 2019.
Patients with left-sided heart failure who get implanted devices to improve the pumping of their hearts may be more likely to develop heart failure on the opposite side of their hearts if they are pre-treated with off-label selective vasodilator drugs, according to new research published in Circulation: Heart Failure, an American Heart Association journal. McGowan Institute for Regenerative Medicine Deputy Director Robert Kormos, MD, FAHA, Professor of Cardiothoracic Surgery and Bioengineering at the University of Pittsburgh, past director of UPMC’s Artificial Heart Program, and the Brack G. Hattler Chair of Cardiothoracic Transplantation, is a co-author on this study.
Technology developed in the McGowan Institute Medical Devices Lab under the leadership of William Federspiel, PhD, William Kepler Whiteford Professor of Bioengineering, Chemical Engineering, and Critical Care Medicine has been incorporated into products for clinical use by ALung, a University of Pittsburgh spinout company. Dr. Federspiel is the Head of the Scientific Advisory Board and co-founder of ALung Technologies, Inc. The ALung devices are now being evaluated in several clinical trials. ALung is the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure.
McGowan Institute for Regenerative Medicine affiliated faculty member Joseph Glorioso III, PhD, Co-founder, CODA Biotherapeutics, and Professor and Emeritus Chair, Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, is working on a gene therapy approach for treating chronic pain. CODA is developing engineered neurotransmitter receptors that are activated exclusively by orally bioavailable drugs to control the activity of hyperexcitable neurons responsible for chronic neuropathic pain. The gene encoding the receptor is delivered to dysfunctional neurons by proprietary viral vectors that are optimized for robust and targeted gene transfer. Standard neurosurgical procedures are used to administer these viral vectors directly to the neurons to be controlled. Once expressed, the engineered receptor can be activated by the drug to modulate neuronal activity. This enables the selective, tunable and reversible regulation of the receptor – and hence cellular activity – based on the dosing regimen of the drug. CODA is engineering receptors to have exquisite sensitivity for the pharmacological activator, which should dramatically limit off-target side effects that plague many pharmaceutical treatments.
The McGowan Institute for Regenerative Medicine held its 2019 Scientific Retreat March 11-12, 2019. The focus was on peer-to-peer networking, and the retreat provided many opportunities to explore collaborative endeavors with other researchers, participating guests, and external partners who are working to bring regenerative medicine technologies to clinical use.
Congratulations to McGowan Institute for Regenerative Medicine deputy director Stephen Badylak, DVM, PhD, MD, professor in the Department of Surgery at the University of Pittsburgh and director of the Center for Pre-Clinical Tissue Engineering within the McGowan Institute, as his h-index (Scopus) has reached 100. The h-index is an author-level metric that attempts to measure both the productivity and citation impact of the publications of a scientist. The index is based on the set of the scientist’s most cited papers and the number of citations that they have received in other publications.
Julie Grant, reporting for Pittsburgh’s local CBS affiliate, KDKA, recently visited with McGowan Institute for Regenerative Medicine affiliated faculty member George Gittes, MD, Director of the Richard King Mellon Foundation Institute for Pediatric Research and Co-Scientific Director at UPMC Children’s Hospital of Pittsburgh of UPMC. She learned that reversing autoimmune type 1 diabetes without immunosuppression has proven to be extremely difficult, but Dr. Gittes and researchers at Children’s Hospital and the University of Pittsburgh School of Medicine have achieved that outcome in pre-clinical trials with an engineered, safe virus that does gene therapy.
One of the downsides to getting older is that skeletal muscle loses its ability to heal after injury. New research from the University of Pittsburgh implicates the so-called “longevity protein” Klotho, both as culprit and therapeutic target.
Mary Kekatos Health Reporter for the Dailymail.com and the Dailymail.com Reporter, recently detailed in her article that statins could prevent the spread of breast cancer, per a new study. Researchers say the drugs, which combat high cholesterol, do not prevent the cancer from occurring but stop it from spreading to other organs. Experiments performed in human cells and laboratory mice found that the pills prevent tumors from migrating to the lungs and liver.
ECM Therapeutics, Inc. has licensed multiple extracellular matrix (ECM) technologies developed in the laboratory of Stephen Badylak, DVM, PhD, MD (pictured top), including hydrogels, bioactive derivatives and methods for delivering these materials within the body. Dr. Badylak is a professor in the Department of Surgery, a deputy director of the McGowan Institute for Regenerative Medicine, and the director of the Center for Pre-Clinical Tissue Engineering within the Institute.
Sponsored by the Pittsburgh Business Times, the 2018 Health Care Hero Awards honor the individuals, companies, and organizations in western Pennsylvania for their contributions to improving health care in our region.
Platelet-rich plasma (PRP) is believed to provide pain relief and help to improve joint function in degenerative joint disease, but a new study—coauthored by McGowan Institute for Regenerative Medicine affiliated faculty member Rocky Tuan, PhD, Vice-Chancellor and President of The Chinese University of Hong Kong—has shown that it does not act by promoting stem cell proliferation or enhance the cartilage formation capabilities of mesenchymal stem cells (MSCs). The effects of PRP treatment on cartilage formation and chondrogenesis in the presence of adult human MSCs derived from two different sources are reported in the study published in Tissue Engineering, Part A, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
In the Pitt Summer 2018 edition, author Jennie Dorris highlights the career paths of McGowan Institute for Regenerative Medicine affiliated faculty member James Funderburgh, PhD, Professor of Ophthalmology and Cell Biology & Physiology, University of Pittsburgh School of Medicine, and his wife, Martha Funderburgh, MPH, Lab Manager and Sr. Research Technician, Corneal Cell Biology Laboratory, Department of Ophthalmology, University of Pittsburgh School of Medicine. The story provides “an exciting outlook for a research team inspired by personal experience and driven by the desire to help others see a brighter future.”
The Controlled Release Society has announced that McGowan Institute for Regenerative Medicine faculty member and University of Pittsburgh professor Steven Little, PhD, is the recipient of its 2018 Young Investigator Award. The honor annually recognizes one individual in the world, 40 years of age or younger, for outstanding contributions to the science of controlled release. Dr. Little is the William Kepler Whiteford Endowed Professor and Chair of the Department of Chemical and Petroleum Engineering at Pitt’s Swanson School of Engineering.
LyGenesis, Inc., a biotechnology company developing innovative technology for organ regeneration, announced recently that they have raised $3 million in Series A financing from Juvenescence, Ltd. LyGenesis’ technology uses lymph nodes as bioreactors to regrow functioning organs within a patient’s own body. The financing will enable LyGenesis to complete the final preclinical work required to enable human clinical trials, which will initially focus on patients with end stage liver disease.
William Wagner, PhD, director of the McGowan Institute for Regenerative Medicine and professor of Surgery, Bioengineering and Chemical Engineering at the University of Pittsburgh, has been selected as the 2018 Inventor of the Year by the Pittsburgh Intellectual Property Law Association.
Photo by Michael Drazdzinski
The McGowan Institute for Regenerative Medicine held its 2018 Scientific Retreat March 5-6, 2018. The focus was on peer-to-peer networking, and the retreat provided many opportunities to explore collaborative endeavors with other researchers, participating guests, and external partners who are working to bring regenerative medicine technologies to clinical use.
Per the United Network for Organ Sharing, every ten minutes, someone is added to the national transplant waiting list in need of a kidney, liver, pancreas, heart, lung, or intestine, the most needed organs of 2017. As of the end of January 2018, there were 114,883 people needing a lifesaving organ transplant (total waiting list candidates) with 74,722 of those people being active waiting list candidates. Tragically, on average, 20 people die each day while waiting for a transplant. More than 7,000 candidates died in 2016 while on the wait list, or within 30 days of leaving the list for personal or medical reasons, without receiving an organ transplant.
Reversing autoimmune type 1 diabetes without immunosuppression has proven to be extremely difficult, but in a study published in Cell Stem Cell, researchers at Children’s Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine report achieving that outcome in mice using gene therapy.
Western Pennsylvania has long been a hub for innovation. This year the Pittsburgh Business Times (PBT) introduced its Innovation Awards, a program that recognizes those that made extraordinary advances in their respective fields, challenging conventional thinking. They are the disruptors, creating new products and developing new approaches that challenge traditional approaches. The McGowan Institute for Regenerative Medicine was selected as one of the winners of this inaugural award for its pioneering development and clinical implementation of regenerative medicine-based therapies. Also, the Human Engineering Research Laboratory under the leadership of McGowan Institute affiliated faculty member Rory Cooper, PhD, was recognized for the development of the PneuChair (TM) pneumatic wheelchair as a PBT Innovation Award winner. The third awardee that has a McGowan Institute relationship is Qrono, Inc. This Pittsburgh start-up was formed by McGowan Institute faculty member Steven Little, PhD, and his former graduate student Sam Rothstein, PhD.
Since the formation of the McGowan Center for Artificial Organ Development (1992) and the McGowan Institute for Regenerative Medicine (2001) there have been many accomplishments advancing the science and clinical achievements in regenerative medicine-based therapies. We see progress in the areas of medical devices, tissue engineering and cell-based therapies, and the prospects for the future are many. Thanks for the opportunities and outcomes created by all who participate in or support the initiatives of the McGowan Institute. Best wishes for another successful year!
In roughly 48 hours, the single cell of the fertilized frog egg will undergo dramatic change to develop vital body parts like muscles, a skeleton, eyes, a heart, and a tadpole tail. Scientists have been studying this process to better understand human development, birth defects, and cancer and to advance technologies like organoid generation and cell replacement therapy. Scientists can disrupt embryo development, pause it, and accelerate it; however, they can’t exactly explain how development works. Supported by the National Institutes of Health (NIH), bioengineers at the University of Pittsburgh are taking a crack at understanding what is going on inside the egg.
Recently reported by PittWire, many people have suffered through an itchy skin rash after a brush with poison oak, wearing jewelry containing nickel, or using latex gloves.
McGowan Institute for Regenerative Medicine affiliated faculty member Julie Phillippi, PhD, Assistant Professor in the Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, received NIH funding for her project entitled “Matrix mediated vasa vasorum dysfunction in thoracic aortic disease.” The funding period is August 2017 through June 2022. The total award is $1,901,221.
Researchers from Virginia Tech and the University of Pittsburgh have collaborated to employ a novel nanoscale fibrous system that can measure the tiny forces exerted by and upon individual cells with extreme precision. The team hopes that this platform, which investigators call nanonet force microscopy (NFM), will provide new knowledge about smooth muscle cell biology that could have implications for treating cardiovascular disease, which is still a leading cause of death in the United States.
The work of McGowan Institute for Regenerative Medicine faculty member Marina Kameneva, PhD, Research Professor of Surgery at the University of Pittsburgh School of Medicine, Professor of Bioengineering, University of Pittsburgh, and Director of the Artificial Blood Program at the McGowan Institute, and colleagues recently appeared in the May 31, 2017, online issue of the publication, Oncotarget. Co-authors on the paper are Samer Tohme, Hamza O. Yazdani, Vikas Sud, Julie Goswami, Patricia Loughran, Hai Huang Richard L. Simmons, and Allan Tsung, all of the University of Pittsburgh.
University of Pittsburgh and UPMC researchers are paving the way for genome-targeted treatments in pancreatic cancer, an especially deadly form of cancer with few existing therapeutic options, according to a pair of recent studies.
The Carnegie Science Center established the Carnegie Science Awards program in 1997 to recognize and promote outstanding science and technology achievements in western Pennsylvania. The Carnegie Science Awards have honored the accomplishments of more than 500 individuals and organizations whose contributions in the fields of science, technology, and education have impacted our region’s industrial, academic, and environmental vitality.
The McGowan Institute for Regenerative Medicine held its 2017 Scientific Retreat on March 5-7, 2017. The retreat provided many opportunities to explore collaborative endeavors with other researchers, participating guests, and external partners who are working to bring regenerative medicine technologies to clinical use. The 2017 Retreat program included technical and strategic planning sessions. The program was designed to facilitate insightful discussions and to identify opportunities for partnerships and new initiatives.
The National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS), recently honored its 2016 Papers of the Year—the top 25 of 2700 publications. In that elite group, McGowan Institute for Regenerative Medicine faculty member Fabrisia Ambrosio, PhD, MPT, Director of Rehabilitation for UPMC International and an Associate Professor in the Department of Physical Medicine & Rehabilitation at the University of Pittsburgh, and her team were recognized for their paper entitled “Arsenic promotes NF-kB-mediated fibroblast dysfunction and matrix remodeling to impair muscle stem cell function,” published in the journal Stem Cells. McGowan Institute faculty member Donna Stolz, PhD, Associate Director of the Center for Biologic Imaging, University of Pittsburgh School of Medicine, and an Associate Professor in the Departments of Cell Biology and Pathology at the University of Pittsburgh, is a co-author on the study.
McGowan Institute for Regenerative Medicine faculty members–
are the principal investigators on a recently funded R01 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health entitled “Ambulatory Assist Lung for Children.”
William R. Wagner, PhD, Director of the McGowan Institute for Regenerative Medicine and Professor of Surgery, Bioengineering & Chemical Engineering at the University of Pittsburgh, has been named a Fellow of the National Academy of Inventors (NAI). Election to NAI Fellow status is the highest professional distinction accorded solely to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society. Academic inventors and innovators elected to the rank of NAI Fellow status have been nominated by their peers for outstanding contributions to innovation in areas such as patents and licensing, innovative discovery and technology, significant impact on society, and support and enhancement of innovation. The 2016 Fellows Gala and Induction Ceremony will take place as part of the NAI 6th Annual Conference on April 6, 2017, in Boston.
To the 230+ scientists, engineers and clinicians that are part of the team of professionals who are committed to the development and translation of regenerative medicine and medical device-based therapies
Results of a study recently published online in the Journal of Crohn’s and Colitis indicated positive results from a preclinical study to assess the effectiveness of a hydrogel for the treatment of Inflammatory Bowel Disease (IBD). The study was led by McGowan Institute for Regenerative Medicine deputy director Stephen Badylak, DVM, PhD, MD, in collaboration with Asana Medical, Inc. The study focused on effectiveness of an ExtraCellular Matrix Hydrogel (ECMH) in the treatment of IBD. Asana has a field-limited exclusive license to certain patent rights for this technology from the University of Pittsburgh.
The Clinical and Translational Science Institute (CTSI) sponsored the 4th Pitt Innovation Challenge. This year’s challenge was focused on bold solutions in health. CTSI aims to move health-related research projects along the translational spectrum, not just to commercialization. Ideas and solutions did not need to be products ready for commercialization—basic science projects were encouraged to apply. In addition, the program encouraged new connections within the academic community, and among universities and community organizations, to foster an ecosystem of innovation.
A study from the McGowan Institute for Regenerative Medicine identifies a mechanism by which bioscaffolds used in regenerative medicine influence cellular behavior, a question that has remained unanswered since the technology was first developed several decades ago. The findings were recently published online in Science Advances.
Results of a study conducted by researchers at the McGowan Institute for Regenerative Medicine and the University of Pittsburgh School of Medicine showed significant improvement in strength and range of motion, as well as evidence for skeletal muscle regeneration, in 13 patients who were surgically implanted with bioscaffolds derived from pig tissue to treat muscle injuries. The patients had failed to respond to conventional treatment before use of the extracellular matrix (ECM). The findings were published online in npj Regenerative Medicine.
The University of Pittsburgh has witnessed more than 120 startup companies launched based on Pitt-developed inventions since 1996. McGowan Institute for Regenerative Medicine deputy director Paulo Fontes, MD, FACS, UPMC transplant surgeon and associate professor, Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, received a 2016 Pitt Innovator Award for his scientific discovery, which has been patented (WO2014059316 A1, PCT/US2013/064607) and further licensed by VirTech Bio LLC, Beverly, Massachusetts. This project was originally sponsored by a charitable fund from the Virginia Garcia de Souza (VGS) Foundation, Sao Paulo, SP, Brazil. It creates a new technology for organ and tissue preservation based on the combined use of machine perfusion and a new hemoglobin-based oxygen carrier solution. Recently, Dr. Fontes received his award from Chancellor Patrick Gallagher, Provost Patricia Beeson, and Senior Vice Chancellor for the Health Sciences and Dean of the School of Medicine, Arthur Levine (all pictured with Dr. Fontes).
The University of Pittsburgh Innovation Institute honored Pitt Innovators whose inventions were recently licensed at its 11th Annual Celebration of Innovation. Also recognized were Pitt faculty, students, and staff who received patents or submitted invention disclosures since July 1, 2014.
The pioneering research led by Paulo Fontes, MD, FACS, UPMC transplant surgeon, associate professor, Starzl Transplantation Institute, Department of Surgery, Pitt School of Medicine, and a deputy director of the McGowan Institute in the development of a new hemoglobin-based oxygen carrier (HBOC) for organ and tissue preservation in combination with machine perfusion (MP) has been selected as a 2016 TechConnect Innovation Awardee. The TechConnect Innovation Awards selects the top early-stage innovations from around the world through an industry-review process of the top 15% of annually submitted technologies into the TechConnect National Innovation Summit. Rankings are based on the potential positive impact the submitted technology will have on a specific industry sector
